Article
Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2006
Rosell Rafael, Taron Miquel, Reguart Noemi, Isla Dolores, Moran Teresa
Abstract excerpt
The discovery of epidermal growth factor receptor (EGFR) mutations in never-smokers has been the most relevant finding ever in non-small cell lung cancer. When patients whose tumors bear the sensitizing mutations are treated with the tyrosine kinase inhibitors gefitinib or erlotinib, we witness response rates and durations never before reported, including complete responses. At the same time, the presence of EGFR...
Topics
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Biomarkers, Tumor
- Brain Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Cetuximab
- Clinical Trials as Topic
- DNA Mutational Analysis
- Disease Progression
